Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of indoleacrylic acid in preparing drug for preventing and treating rheumatoid arthritis

A technology of indoleacrylic acid and rheumatoid, which is applied in the direction of drug combination, antipyretics, anti-inflammatory agents, etc., and can solve problems such as pulmonary interstitial lesions, difficult to cure, and incurable diseases

Active Publication Date: 2019-04-16
PEOPLES HOSPITAL PEKING UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, the treatment of rheumatoid arthritis is limited to the use of drugs to relieve the disease, which is difficult to cure
However, long-term use of immunosuppressants cannot cure the disease, and it is easy to cause recurrence after drug withdrawal, and it will cause complications such as pulmonary interstitial lesions and adverse reactions such as infection and rash. Tolerance of the treatment is particularly important

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of indoleacrylic acid in preparing drug for preventing and treating rheumatoid arthritis
  • Application of indoleacrylic acid in preparing drug for preventing and treating rheumatoid arthritis
  • Application of indoleacrylic acid in preparing drug for preventing and treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Indoleacrylic acid significantly inhibits the development of experimental arthritis

Embodiment approach

[0031] (1) Constructing a collagen-induced joint (CIA) model: 1) Dissolving collagen, dissolving bovine type II collagen (CII) in 0.1mol glacial acetic acid, adjusting the final concentration of CII to 4mg / mL, and overnight at 4°C. 2) Emulsifying collagen, mixing completely dissolved CII with an equal volume of Freund's complete adjuvant (CFA) to fully emulsify the two to prepare a collagen emulsion with a final concentration of 2 mg / mL. 3) For the first immunization, the base of the tail of the mice was depilated, and a total of 200 μg of collagen emulsion was injected intradermally at multiple points. 4) Booster immunization. On the 21st day after the initial immunization, dissolve type II collagen in 0.1mol glacial acetic acid (concentration 4mg / mL), add an equal volume of incomplete Freund's adjuvant (IFA) to make collagen emulsion (final concentration 2mg / mL). A total of 100 μg of collagen emulsion was injected intradermally at multiple points at the base of the tail. ...

Embodiment 2

[0039] Indoleacrylic acid regulates the ratio of lymphocyte subsets in CIA mice

[0040] method of execution

[0041] Flow cytometry to detect the proportion of lymphocyte subsets: Isolate the joint draining lymph nodes (axillary and popliteal lymph nodes), mesenteric lymph nodes and spleen of CIA mice, use 1640 medium and filter to grind the lymph nodes into a single cell suspension, and adjust the number of cells 2-3 x 10 6 / 100μl, add staining flow antibody (eBioscience, U.S.A.), wash and resuspend, and use the machine (BDFACSAria TM II) Detection. see results figure 2 .

[0042] Research result

[0043] From figure 2 It can be concluded that the analysis of lymphocyte subsets showed that indoleacrylic acid significantly down-regulated the proportion of T helper cells Th1 in joint-draining lymph nodes (DLN) (attached figure 2 a, CIA group Th12.1±0.1755vs IA group Th11.383±0.1425), while the ratio of Th17 cells, follicular helper T cells Tfh and regulatory T cells ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of indoleacrylic acid in preparing a drug for preventing and treating rheumatoid arthritis, and relates to the technical field of rheumatoid arthritis treatment. Theindoleacrylic acid can significantly inhibit the development of experimental arthritis and effectively relieve the symptom of arthrocele. Further studies find that the indoleacrylic acid can down-regulate the proportion of pro-inflammatory cells Th1 and Tfh cells in mesenteric lymph nodes, articular lymph nodes and the spleen, and increase the expression of Treg (regulatory T cells) cells. In addition, the indoleacrylic acid can also reduce the concentration of pro-inflammatory factors IL-1 beta and IL-6 in serum, significantly improve the intestinal flora of arthritic mice, increase the species diversity of the flora and enrich the beneficial bacteria. The enriched beneficial bacteria are associated with the relief of the arthritis symptoms and inhibition of immune response, and participate in the anti-inflammatory and immunomodulatory processes of the indoleacrylic acid. The indoleacrylic acid can adjust abnormal immune cells in the targeting mode, treat diseases from an upstream pathway and regulate immune balance.

Description

technical field [0001] The invention relates to the technical field of treating rheumatoid arthritis, in particular to the application of indole acrylic acid in the preparation of drugs for preventing and treating rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis is a common chronic systemic autoimmune disease characterized by symmetrical polyarthritis and the production of autoantibodies (rheumatoid factor, anti-citrullinated protein antibody). The prevalence of rheumatoid arthritis in my country is 0.28-0.41%, with as many as 5 million patients. For patients without formal treatment, the disease will gradually progress, eventually leading to joint deformity, and the 3-year disability rate is as high as 75%. The disability caused by rheumatoid arthritis seriously affects the quality of life of patients, and the subsequent high medical expenses have brought huge economic pressure to families and society. [0003] The combined effect of genetics and v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/405A61P29/00A61P19/02
CPCA61K31/405A61P19/02A61P29/00
Inventor 栗占国李静靳家扬何菁贾汝琳金月波
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com